Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention leads to lower grade 3 to 4 neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
The intervention probably leads to lower grade 3 to 4 neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 neutropenia · people with metastatic colorectal cancer
The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review